1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. p38 MAPK
  4. p38α Isoform



p38α Related Products (36):

Cat. No. Product Name Effect Purity
  • HY-10295
    SB 202190
    Inhibitor 99.89%
    SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively.
  • HY-10320
    Inhibitor 99.98%
    Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM.
  • HY-13241
    Ralimetinib dimesylate
    Inhibitor 99.52%
    Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively.
  • HY-10328
    Inhibitor 99.32%
    Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC50 for p38α of 10 nM and for p38β of 220 nM.
  • HY-112089
    Inhibitor 99.95%
    LXH254 is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively.
  • HY-146032
    p38-α MAPK-IN-4
    p38-α MAPK-IN-4 (Compound 69) is a selective p38α MAPK inhibitor with an IC50 of 1.5 µM.
  • HY-147518
    p38-α MAPK-IN-5
    p38-α MAPK-IN-5 (compound 4e) is a potent p38α inhibitor with IC50s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively.
  • HY-144697
    p38 MAPK-IN-3
    p38 MAPK-IN-3 (Compound 2c) is a p38α MAPK inhibitor.
  • HY-10456
    Inhibitor 99.89%
    TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively.
  • HY-10406
    Inhibitor 98.04%
    Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM.
  • HY-14305A
    BMS-582949 hydrochloride
    Inhibitor 98.29%
    BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM.
  • HY-120111
    Inhibitor 99.90%
    MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM.
  • HY-10405
    Inhibitor 99.92%
    Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively.
  • HY-114423
    p38α inhibitor 1
    Inhibitor 98.30%
    p38α inhibitor 1 is a p38α inhibitor extracted from patent WO 2008076265 A1.
  • HY-108642B
    AMG-548 dihydrochloride
    Inhibitor 99.85%
    AMG-548 dihydrochloride, an orally active and selective p38α inhibitor (Ki=0.5 nM), shows slightly selective over p38β (Ki=36 nM) and >1000 fold selective against p38γ and p38δ.
  • HY-135674
    Inhibitor 98.87%
    SR-318 is a potent and highly selective p38 MAPK inhibitor with IC50s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively.
  • HY-14975
    R1487 Hydrochloride
    Inhibitor 98.94%
    R1487 Hydrochloride is a highly potent and selective p38α inhibitor, with Kd values of 0.2 nM and 29 nM for p38α and p38β, respectively.
  • HY-15505
    Inhibitor 99.32%
    RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively.
  • HY-W015445
    Inhibitor 99.44%
    SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM.
  • HY-112182
    Inhibitor 98.91%
    UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a Kd of 2.7 nM.